How is molecular barcoding recycling non-cancer drugs to treat cancer?
The medical and pharmaceutical community has been laser-focused on researching and developing new therapeutics for cancer, what’s known as the ‘de novo’ drug discovery process, when, in fact, existing non-cancer drugs can be repurposed to fight cancer.Drug repurposing – or repositioning or redirection – can accelerate patients’ access to beneficial therapeutics while reducing costs of drug development. In de novo drug discovery, time between discovery and clinical trials is 9 years on average, with a success rate of less than 10%, and an average cost per drug to the patient of several hundred million dollars [1]. By contrast, in drug repurposing,...